Country for PR: United States
Contributor: PR Newswire New York
Monday, October 31 2022 - 23:00
EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine
PROVIDENCE, R.I., Oct. 31, 2022 /PRNewswire-AsiaNet/ --

EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project 
with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness 
Innovations), to develop universal vaccines for betacoronaviruses, including 
SARS-CoV-2. EpiVax will be carrying out the vaccine epitope selection portion 
of the collaboration using their comprehensive in silico vaccine design toolkit 
"iVAX" ( 

Logo -

This program is funded under CEPI's 2021 call for proposals ( 
) to accelerate the development of broadly protective coronavirus vaccines, 
which will provide up to US$200 million for such projects. Intravacc was 
awarded $4.8 million to advance their subunit vaccine candidate "Avacc 101" ( 
), which is designed for intranasal delivery to provide protective immunity for 
multiple betacoronaviruses including SARS-CoV-1, SARS-CoV-2, and MERS-CoV. 
Avacc 101 uses Intravacc's Outer Membrane Vesicle (OMV) technology ( 
) to deliver vaccine payloads for an effective immune response.

As a subgrantee on the project, EpiVax will identify cross-reactive 
beta-coronavirus T cell epitopes for broad coverage of COVID-19, MERS and SARS 
Class 1 and Class 2 HLA-restricted epitopes, using the iVAX in silico vaccine 
design toolkit ( 
). In addition to vaccine epitope selection, EpiVax will also develop multiple 
designs, and will validate these in silico constructs in vivo with 
HLA-transgenic mice.

According to EpiVax CEO/CSO Dr. Annie De Groot, "We sincerely appreciate the 
opportunity to apply our advanced vaccine design tools to a problem of global 

About EpiVax:

EpiVax is a biotechnology company with expertise in T cell epitope prediction, 
immune modulation, and rapid vaccine design. EpiVax's immunogenicity screening 
toolkits for therapeutics and vaccines, ISPRI and iVAX, are employed in 
advancing the research of a global roster of companies. For more information, 

About Intravacc:

Intravacc is a leading global contract development and manufacturing 
organization (CDMO) of innovative vaccines against infectious diseases. 
Intravacc has transferred its technology related to polio vaccines, measles 
vaccines, DPT vaccines, Hib vaccines and influenza vaccines around the world. 
Intravacc offers a wide range of expertise to develop vaccine from concept to 
Phase I/II clinical studies for academic, industry and philanthropic partners. 
For more information, visit

Press Contact:
Katie Porter, Associate Director, Business Development & Marketing

Source: EpiVax Inc.